Format

Send to

Choose Destination
Eur J Clin Pharmacol. 2018 May;74(5):619-626. doi: 10.1007/s00228-017-2406-0. Epub 2018 Jan 6.

Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users.

Author information

1
Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, University Bordeaux, F-33000, Bordeaux, France. francois.montastruc@univ-tlse3.fr.
2
Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de Toulouse, Centre Hospitalier Universitaire, Toulouse, France. francois.montastruc@univ-tlse3.fr.
3
Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, University Bordeaux, F-33000, Bordeaux, France.
4
CHU Bordeaux, Pole de Santé Publique, Centre Régional de Pharmacovigilance de Bordeaux, Service de Pharmacologie Médicale, F-33000, Bordeaux, France.

Abstract

PURPOSE:

The present study was conducted to describe antipsychotic (AP) prevalent and incident use, characteristics of AP users, and their trends in the French population.

METHODS:

A cross-sectional study was repeated yearly from January 1, 2007 to December 31, 2013 (for prevalence analysis) or to December 31, 2012 (for incidence analysis) using the French Health Insurance reimbursement database (Echantillon Généraliste de Bénéficiaires, EGB). For each year studied, prevalent and incident AP users were described in terms of age and gender overall, and according to the type of AP (FGAPs or SGAPs) used at index date. In addition, concurrent medications and comorbidities that a priori contraindicate the use of drugs having atropinic properties were researched.

RESULTS:

Prevalence and incidence remained relatively stable along the 2007-2013 period. Trends slightly decreased, from 2.07% (n = 10,252) to 2.05% (n = 11,015) for prevalence, and from 0.73% (n = 3461) to 0.66% (n = 3363) for incidence, especially in elderly, in contrast of children and adolescents (+ 39% for prevalence, from 184 to 271). The number of coprescribed drugs was found high (median = 5) and remained constant over time. In 2013, about 7% of prevalent AP users presented with a comorbidity increasing the risk of atropinic ADRs, and 36% used at least one concurrent atropinic drug. In incident AP users, these numbers were of 8 and 29%, respectively.

CONCLUSIONS:

The present study highlighted a marked shift from FGAPs toward SGAPs, as well as an increase in AP use in children and adolescents in France.

KEYWORDS:

Antipsychotics; Drug utilization; Incidence; Insurance health reimbursement; Pharmacoepidemiology; Prevalence

PMID:
29307053
DOI:
10.1007/s00228-017-2406-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center